Do Decreased CEP17 Signals Indicate the Presence of "Monosomy" in Breast Cancer? A Study of HER2 Gene Status and HER2 Immunohistochemistry.

被引：0

作者：

Tse, C. H. ^{[1
]}

Hwang, H. C. ^{[1
]}

Goldstein, L. C. ^{[1
]}

Kandalaft, P. L. ^{[1
]}

Duesterhoeft, S. M. ^{[1
]}

Kussick, S. L. ^{[1
]}

Gown, A. M. ^{[1
]}

机构：

[1] PhenoPath Labs, Seattle, WA USA

来源：

CANCER RESEARCH | 2011年 / 71卷

关键词：

D O I：

10.1158/0008-5472.SABCS11-P4-09-04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4-09-04

引用

页数：2

共 50 条

[1] High HER2 signals and HER2/CEP17 ratio tumours achieve better responses in breast cancer
Exposito Afonso, I. J.
del Pino Sedeno, T.
Gonzalez Villa, I.
Loro Ferrer, J. F.
Cabrera Galvan, J. J.
VIRCHOWS ARCHIV, 2020, 477 : S45 - S46
[2] Breast Cancers with < 4 HER2 Signals/cell and Amplified HER2:CEP17 Ratios by FISH: Pathologic Features and Clinical Outcomes of Cases with "CEP17 Monosomy"
Ballard, Morgan
Troxell, Megan
Jensen, Kristin
Allison, Kimberly H.
LABORATORY INVESTIGATION, 2017, 97 : 31A - 31A
[3] Breast Cancers with < 4 HER2 Signals/cell and Amplified HER2:CEP17 Ratios by FISH: Pathologic Features and Clinical Outcomes of Cases with "CEP17 Monosomy"
Ballard, Morgan
Troxell, Megan
Jensen, Kristin
Allison, Kimberly H.
MODERN PATHOLOGY, 2017, 30 : 31A - 31A
[4] Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry
Davies, Vanessa
Voutsadakis, Ioannis A.
CANCER INVESTIGATION, 2020, 38 (02) : 94 - 101
[5] HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemotherapy
Livasy, Chad A.
Limentani, Kimberly
Calhoun, Benjamin C.
Limentani, Steven
CANCER RESEARCH, 2015, 75
[6] Utility of HER2 Immunohistochemistry in Clarifying HER2 Status in Breast Cancer with HER2:CEP17 Ratio <2 and Average >/=4.0 and <6.0 HER2 Signals per Tumor Cell by Fluorescence in-situ Hybridization (Focused Update Group 4)
Muller, Kristen
Marotti, Jonathan
Tafe, Laura
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 223 - 223
[7] Utility of HER2 Immunohistochemistry in Clarifying HER2 Status in Breast Cancer with HER2:CEP17 Ratio <2 and Average >/=4.0 and <6.0 HER2 Signals per Tumor Cell by Fluorescence in-situ Hybridization (Focused Update Group 4)
Muller, Kristen
Marotti, Jonathan
Tafe, Laura
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 223 - 223
[8] Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha
Islam M. Miligy
Cecily M. Quinn
Elena Provenzano
Abeer M. Shaaban
Caterina Marchiò
Michael S. Toss
Grace Gallagy
Ciara Murray
Janice Walshe
Ayaka Katayama
Karim Eldib
Nahla Badr
Bruce Tanchel
Rebecca Millican-Slater
Colin Purdie
Dave Purnell
Sarah E. Pinder
Ian O. Ellis
Andrew H. S. Lee
British Journal of Cancer, 2021, 124 : 1836 - 1842
[9] Incidence and Significance of Fluorescent In Situ Hybridization (FISH) HER2 Gene Amplification by HER2 Gene Copy Number of ≥6.0 with Her2/CEP17 Ratio of <2.0 in Breast Cancer
Apple, Sophia
MODERN PATHOLOGY, 2017, 30 : 29A - 30A
[10] A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of <4.0 signals per cell
Wang, Xiaoling
Teng, Xiaodong
Ding, Wei
Sun, Ke
Wang, Bo
MODERN PATHOLOGY, 2020, 33 (08) : 1557 - 1562

← 1 2 3 4 5 →